We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 1.73% | 44.00 | 43.00 | 45.00 | 44.00 | 43.25 | 43.25 | 290,844 | 08:19:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 23.25M | -24.95M | -0.0695 | -6.33 | 155.29M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/9/2024 16:30 | lol 1347....er, so you don't know the answer or have any evidence despite writing with such authority. Rajraj's possible explanation sounds plausible but no doubt that'll be 'confirmation bias'. | cheshire pete | |
14/9/2024 12:18 | If they had found the MTD at a much lower dose the trial would have finished P1 ages ago but the expectation of what the potential is here would then be poor so I'm all for it taking its time for this particular reason. | rajraj b | |
14/9/2024 12:11 | I think they didn't expect not to find a MTD. this is what has slowed everything down. Even in the 2 week trial they haven't found a MTD. Yes it slows the process down as you would do your best to identify it. Pretty impressive stuff. | rajraj b | |
14/9/2024 09:53 | @cp Well you'd have to ask Avacta that, they are running the trials, but I bet you won't get an answer. Possibly they could have modelled it to get to the optimum dosage quicker rather than everything being done empirically and sequentially. It's not normal for Phase 1 trials to take over 3 years. | 1347 | |
14/9/2024 08:40 | It Works™ | vertizeasun | |
14/9/2024 07:47 | https://avacta.com/w | rajraj b | |
14/9/2024 07:34 | https://avacta.com/a | rajraj b | |
14/9/2024 07:26 | Yes the Covid test lost out by Johnson importing millions of tests from China through a £50 off the shelf company, and when challenged in the Commons shouting that he supported the British diagnostic sector The Scots producer of tests was then taken over by the Chinese for a pittance | sandcrab2 | |
13/9/2024 21:19 | We may not have long to wait for the data. Timescales dictated by regulatory and medical requirements rather than satisfying the impatient looking for the next quick buck or short trade. Do you have evidence 1347 that things could have been done quicker? Chartists saying 200 day moving average crossed recently lol. | cheshire pete | |
13/9/2024 20:28 | Same question to you then 1347. What's not to like? | cheshire pete | |
13/9/2024 18:25 | People buying on an article by MM, a known ramper, who has been proven to be wrong time after time, what could possibly go wrong? | 1347 | |
13/9/2024 17:31 | Even when Avct is taken over, he will argue against it. | divmad | |
13/9/2024 17:23 | Jaknife: Are you saying there's something in the above by MM that you think is incorrect? If so, pray tell the rest of us. | cheshire pete | |
13/9/2024 15:57 | Then go by what Avacta is saying publicly in its R&D notes and the Esmo conf data. | divmad | |
13/9/2024 15:51 | Jaknife , erm Covid , really | jacktrax | |
13/9/2024 15:05 | Powerful summation by Myles there | sandcrab2 | |
13/9/2024 14:27 | Who to believe: Jaknife, repins, whitey, MylesM? Know where my money is. Should add copied from LSE. | cheshire pete | |
13/9/2024 12:57 | "So, whilst in 2033/34 (approximately when the family of patents expire for the D-Ala-Pro substrate), other companies may start to use the 1stgeneration format for developing PDCs, they could not develop 2nd generation PDCs (unless under license from Avacta or whoever owns the technology then). And why bother attempting to develop a 1st generation PDC in the mid-2030s, when the owner of the 2nd generation technology (which would be on-patent for another decade at that point) could simply develop a superior molecule?" | vertizeasun | |
13/9/2024 07:04 | Cheshire/ Fieldhouse ...I do understand your enthusiasm, really I do. Things look spot on. Data looks good, cash position looks ok for now etc. I just can't work out why the main guy walked- his baby etc+ when on the cusp of a major breakthrough, more share options etc etc. I detest Aim. It s bandit country. Many pi.s lose their pants and are never seen again. Must have a well balanced portfolio but greedy takes most. We wait. Good luck fellas ... Ps share price is strong/ steady | amanitaangelicus | |
12/9/2024 19:55 | Am,Smiths comment that a fundraise was nothing to worry about when the share price was north of a £ and then raise at 50p was UNFORGIVABLE.Big investors would have wanted his head . Simple | fieldhouse | |
12/9/2024 19:26 | No idea why he stepped down ama, could have been for many reasons. Careful with those conspiracy theories though. AIM has seen some great companies start up, Avacta could be the next. | cheshire pete | |
12/9/2024 18:35 | Poster presentation this weekend, should see a Monday company update. | robers98 | |
12/9/2024 18:09 | THE AVCT SHARE PRICE And when they were up they were up, And when they were down they were down, And when they were only half way up They were neither up nor down. RESULTS SHOULD SOON CLARIFY share price DIRECTION GOOD LUCK ALL | waldron |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions